1811 Expression levels of ERBB2, ESR1, immune and...

European Journal of Cancer 2015 / 09 Vol. 51

1811 Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial

Sotiriou, C., Venet, D., Fumagalli, D., Maetens, M., Rothé, F., Ignatiadis, M., Bradbury, I., Harbeck, N., Gomez, H., Chang, T.W., Coccia-Portugal, M.A., Di Cosimo, S., De Azambuja, E., De la Pena, L.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)30764-x
Date:
September, 2015
File:
PDF, 59 KB
english, 2015
Conversion to is in progress
Conversion to is failed